April 5, 2021 -- Anixa Biosciences and OntoChem are progressing to the next stage of development of an antiviral therapy for COVID-19.
The therapy will be orally administered and room-temperature stable. The two firms have completed proof-of-concept animal studies that evaluated potential compounds and compared them with remdesivir.
The firms plan to use combinatorial synthetic medicinal chemistry to evaluate whether potency can be increased and pharmacokinetics optimized. Promising compounds will again be studied, they said. This stage of development will take four to five months.